Inmune Bio Appoints New CMO, Adds Director
Ticker: INMB · Form: 8-K · Filed: May 16, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | May 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $9.92 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-appointment
Related Tickers: INMB
TL;DR
Inmune Bio shakes up leadership with a new CMO and board member.
AI Summary
On May 14, 2024, Inmune Bio, Inc. announced the appointment of Dr. David M. Siegel as Chief Medical Officer and the election of Ms. Jennifer L. D. Allison to its Board of Directors. The company also reported on compensatory arrangements for its officers. These changes are effective immediately.
Why It Matters
These executive and board changes could signal a shift in the company's strategic direction or operational focus in the biotechnology sector.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- Dr. David M. Siegel (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. D. Allison (person) — Elected to Board of Directors
- May 14, 2024 (date) — Effective date of appointments and elections
FAQ
What are the specific responsibilities of the new Chief Medical Officer, Dr. David M. Siegel?
The filing states Dr. Siegel has been appointed Chief Medical Officer, but does not detail his specific responsibilities beyond this title.
What is Ms. Jennifer L. D. Allison's background and experience that led to her election to the Board of Directors?
The filing announces Ms. Allison's election to the Board of Directors but does not provide details on her background or experience.
Were there any departures of directors or officers mentioned in this filing?
The filing mentions 'Departure of Directors or Certain Officers' as an item, but does not specify any departures in the provided text.
What specific compensatory arrangements for officers are detailed in this report?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not included in the provided text.
What is the primary business of Inmune Bio, Inc. according to the filing?
According to the filing, Inmune Bio, Inc. is in the business of 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Filing Stats: 731 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-05-16 16:00:14
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
- $9.92 — common stock with an exercise price of $9.92 under the Company's 2021 Stock Incentiv
Filing Documents
- ea0206390-8k_inmune.htm (8-K) — 29KB
- ea020639001ex10-1_inmune.htm (EX-10.1) — 31KB
- ea020639001ex10-2_inmune.htm (EX-10.2) — 40KB
- 0001213900-24-044284.txt ( ) — 290KB
- inmb-20240514.xsd (EX-101.SCH) — 3KB
- inmb-20240514_lab.xml (EX-101.LAB) — 33KB
- inmb-20240514_pre.xml (EX-101.PRE) — 22KB
- ea0206390-8k_inmune_htm.xml (XML) — 4KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 14, 2024, the Board of Directors (the "Board") of INmune Bio Inc. (the "Company") approved the issuance of an option to each non-employee director ("Optionee") to purchase 12,500 shares of the Company's common stock with an exercise price of $9.92 under the Company's 2021 Stock Incentive Plan (the "2021 Plan"). The options will become vested and exercisable one-twelfth (1/12) every month until 100% vested, which shall occur on the one (1) year anniversary of the date of grant and expire on May 13, 2034. The Company has executed a nonqualified stock option agreement with each Optionee. On May 14, 2024, the Board approved the issuance of options to Ramond J. Tesi, the Company's Chief Executive Officer, and David Moss, the Company's Chief Financial Officer, to purchase 160,000 shares of the Company's common stock pursuant to incentive stock option agreements and the issuance of options to the Company's Chief Scientific Officer, Mark Lowdell to purchase 100,000 shares of the Company's common stock pursuant to a nonqualified stock option agreement. The options have an exercise price of $9.92 per share. One-fourth (1/4) of the options will vest twelve (12) months from the grant date and thereafter the remaining unvested options will become vested and exercisable on a monthly basis over three (3) years (1/36 per month) until the options are 100% vested which shall occur on the four (4) year anniversary of the grant date. The options were granted from the 2021 Plan and expire on May 13, 2034. The forgoing summary of the option grants referenced above is not complete and qualified in its entirety by reference to the form of nonqualified option agreement and form of incentive stock option agreement, each of which is being filed as Exhibit 10.1 and Exhibit 10.2 to this Current Report on Form 8-K and is incorpora
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit No Description 10.1 Form of Nonqualified Option Agreement of INmune Bio Inc. 10.2 Form of Incentive Stock Option Agreement of INmune Bio Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: May 16, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2